On August 17, 2023, Camac Partners, LLC announced that it has filed a revised preliminary proxy statement with Securities and Exchange Commission, requesting the shareholders of Forte Biosciences to vote for the election of its 2 nominees, Michael G. Hacke and Chris McIntyre, and vote against for the 2 Company nominees, Lawrence Eichenfield and Paul A. Wagner. Additionally, Camac Partners, LLC urged shareholders to vote against Company proposal to approve, on an advisory basis, the compensation of the Company?s named executive officers at its 2023 annual general meeting of shareholders.